

Article

Not peer-reviewed version

Genomic Insights and Antimicrobial Potential of newly *Streptomyces cavourensis* Isolated from a RAMSAR Wetland Ecosystem

Mabrouka Benhadj , [Taha Menasria](#) ^{*} , Nawel Zaatout , [Stéphane Ranque](#) ^{*}

Posted Date: 30 January 2025

doi: 10.20944/preprints202501.2234.v1

Keywords: Wetland; *Streptomyces cavourensis*; antimicrobial activity; whole genome sequencing; bio-active molecules



Preprints.org is a free multidisciplinary platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Article

Genomic Insights and Antimicrobial Potential of newly *Streptomyces cavourensis* Isolated from a RAMSAR Wetland Ecosystem

Mabrouka Benhadj ^{1,2}, Taha Menasria ^{3,*}, Nawel Zaatout ³ and Stéphane Ranque ^{4,*}

¹ Biomolecules and Application Laboratory, Faculty of Exact Sciences and Natural and Life Sciences, Echahid Cheikh Larbi Tebessi University, 12002 Tebessa, Algeria

² Department of Applied Biology, Faculty of Exact Sciences and Natural and Life Sciences, Echahid Cheikh Larbi Tebessi University, 12002 Tebessa, Algeria

³ Department of Microbiology and Biochemistry, Faculty of Natural and Life Sciences, University of Batna 2, 05078 Batna, Algeria

⁴ Aix Marseille University, SSA, RITMES, IHU-Méditerranée Infection, 19- 21 boulevard Jean Moulin, 13005 Marseille, France

* Correspondence: t.menasria@univ-batna2.dz (T.M.); stephane.RANQUE@univ-amu.fr (S.R.)

Abstract: The growing threat of antimicrobial resistance underscores the urgent need to identify new bioactive compounds. In this study, a *Streptomyces* strain ACT158, was isolated from a RAMSAR wetland ecosystem, exhibited broad-spectrum effects against Gram-positive, Gram-negative bacteria, as well as fungal pathogens. The active strain was characterized as *S. cavourensis* according to its morphology, phylogenetic analysis, average nucleotide identity (ANI) and digital DNA–DNA hybridization (dDDH). Whole-genome sequencing (WGS) and annotation revealed a genome size of 6.86 Mb with 5,122 coding sequences linked to carbohydrate metabolism, secondary metabolite biosynthesis, and stress responses. Genome mining through antiSMASH revealed 32 biosynthetic gene clusters (BGCs), including those encoding polyketides, non-ribosomal peptides, and terpenes, many of which showed low similarity to known clusters. Comparative genomic analysis, showing high genomic synteny with closely related strains. Unique genomic features of ACT158 included additional BGCs and distinct genes associated with biosynthesis pathways and stress adaptation. These findings highlight the strain's potential as a rich source of bioactive compounds and provide insights into its genomic basis for antimicrobial production, ecological and biotechnological significance.

Keywords: Wetland; *Streptomyces cavourensis*; antimicrobial activity; whole genome sequencing; bioactive molecules

1. Introduction

Microorganisms have long been harnessed for the production of natural products, particularly due to their ability to synthesize secondary metabolites with significant bioactivity [1]. Among these, actinomycetes, a diverse group of Gram-positive bacteria, are extensively recovered in both natural and manmade environments [2]. They are the key contributors to the biosynthesis of novel and unique secondary metabolites with diverse structures and functions, including antibacterial, antifungal, antitumor, antiprotozoal, and antiviral activities, as well as the production of vitamins and hydrolytic enzymes [3].

The genus *Streptomyces* is a prominent representative of actinomycetes, characterized by aerobic, Gram-positive, non-acid-fast, and multicellular bacteria that form extensively branched substrate and aerial mycelia [4]. Upon maturation, the aerial mycelia differentiate into chains of multiple spores.

Streptomyces are ubiquitous in terrestrial ecosystems and are widely recognized for their remarkable metabolic versatility and adaptability [5]. They play a crucial role in the degradation of organic matter, such as leaf litter, thereby contributing significantly to nutrient cycling and soil fertility [6]. Moreover, *Streptomyces* can metabolize a wide range of complex compounds, including polysaccharides, alcohols, amino acids, and aromatic compounds, through the production of extracellular enzymes such as amylase, chitinase, cellulase, glucanase, and protease [7]. Notably, *Streptomyces* are recognized as the largest antibiotic-producing genus identified in the microbial world to date [8]. In addition to antibiotics, It has the ability to produce other important bioactive secondary metabolites, including antifungals, antivirals, antitumor agents, antihypertensives, and notably, immunosuppressants [3]. As of September 2024, 1228 species and 74 subspecies with 773 validly published and correct names had been approved, as in the List of Prokaryotic names with Standing in Nomenclature [9]. This number continues to increase annually with several dozen newly species being proposed each year.

The recent rise of antibiotic resistance, particularly from carbapenem-resistant bacteria, has become a critical global health concern, complicating the treatment of bacterial infections [10]. These organisms, including strains of *Klebsiella pneumoniae*, *Escherichia coli*, and *Acinetobacter baumannii*, exhibit resistance to carbapenems, which are often considered last-resort antibiotics for multidrug-resistant infections [11]. This growing resistance reduces the effectiveness of existing antibiotics, leading to prolonged illnesses and increased mortality rates. Consequently, the alarming trend underscores the urgent need for research into alternative sources of potent bioactive compounds, especially from actinomycetes [12]. Exploring these sources may yield new antibiotics that can effectively combat resistant strains and enhance therapeutic arsenal against challenging infections [8].

Significant advancements in DNA sequencing technologies have led to a substantial increase in the number of fully sequenced actinomycetes genomes [13]. As a result, a panel of bioinformatics tools for genome annotation and mining have been developed to identify secondary metabolite biosynthetic gene clusters (smBGCs) and predict their location [14]. Recent *In-silico* large-scale studies have highlighted the tremendous potential of *Streptomyces* species for discovering novel and potentially relevant compounds associated with BGCs, many of which remain uncharacterized and underscore the significant untapped biosynthetic potential of *Streptomyces*, particularly those from poorly studied ecological niches [15].

Algeria hosts an exceptional array of wetlands and hypersaline lakes, recognized globally for their unique typology and ecology. Among these, 50 sites are classified as internationally significant Ramsar sites [16]. These ecosystems span diverse climatic zones, from subtropical wetlands in the coastal northeast to semi-arid regions in the Hauts Plateaux and arid regions of the Sahara, fulfilling essential ecological functions [17]. Despite their ecological importance, the microbial diversity and bioactivity within these habitats remain poorly understood. Thus, exploring these unique ecosystems not only enhances our understanding of microbial diversity but also opens avenues for discovering new compounds that can contribute to drug development and ecological sustainability. In this context, the genome of a selected antimicrobial-producer *Streptomyces* strain, isolated from a natural representative RAMSAR wetland in the Mediterranean region (Feztara lake, northeastern Algeria). This study combines genomic, metabolic, and physiological analyses to explore the strain's antimicrobial potential, carbohydrate-active enzymes, and its biosynthetic gene clusters (BGCs).

2. Materials and Methods

2.1. Actinomycete Isolation

The strain ACT158 was isolated from Fetezara lake, using starch casein medium as described by Benhadj et al [18] supplemented with (2.5 µg/ml of rifampicin, 10 µg/ml of amphotericin B and 75 µg/ml of fluconazole). The plates were incubated at 28 °C for 10 days and the strain was

subcultured and maintained on ISP2 agar at 4 °C and at -80 °C on the 20% of glycerol as mycelia suspension.

2.2. Phenotypic and Physiological Characterization

The strain S158 was characterized based on its morphological, physiological, and biochemical traits using standard methods [19,20]. Morphological characterization was conducted according to the International Streptomyces Project (ISP), employing ISP1, ISP2, ISP3, ISP4, ISP5, and ISP6 media. Growth characteristics were observed after 3, 7, 14, and 21 days of cultivation at 30°C. ISP6 and ISP7 were utilized to assess melanoid pigment production. NaCl tolerance, pH and, temperature growth was tested on ISP2 medium. Nitrate reduction, hemolytic activity, and the production of amylase, gelatinase, coagulase, urease, citrate permease, and esterase were analyzed using various media as described by Benhadj et al. [18]. The minimal basal medium (ISP9) was used to determine the capacity of the isolates to use different carbon source at 1% of final concentration and A range of sugars, including arabinose, ribose, rhamnose, mannitol, fructose, sucrose, galactose, mannose, inositol, glucose, and maltose, were tested for acid production.

2.3. MALDI-TOF MS Identification

To characterize ACT158, protein extraction was performed using the ethanol/formic acid EtOH/FA) protein extraction method as described by Cassagne et al. [21]. Subsequently, MALDI-TOF MS analysis was conducted using a Microflex MALDI-TOF mass spectrometer (Bruker Daltonics, Germany). Extracted samples were prepared for analysis by spotting them onto polished MALDI plates and overlaying them with a matrix solution of α -cyano-4-hydroxycinnamic acid (HCCA). Calibration of the spectrometer was performed using *Escherichia coli* DH5 α , and a non-inoculated matrix served as a negative control. To ensure data reliability, sample was analyzed in triplicate and the identification confidence was evaluated based on score thresholds, with scores ≥ 1.9 considered low confidence and scores < 1.7 deemed unreliable. Normalized MALDI-TOF MS spectra of ACT158 and reference strains were subjected to agglomerative hierarchical clustering (AHC) analysis to assess the phylogenetic relationship of ACT158 within the *Streptomyces* genus.

2.4. DNA Extraction, 16SrRNA Gene Sequencing and Phylogenetic Analysis

The genomic DNA of the strain ACT158 was extracted as described by Kieser et al [22]. The 16S rRNA gene was amplified by PCR using a pair of the universal primers Fd1 (5' AGAGTTTGATCCTGGCTCAG) and rP2 (5'-AAGGAGGTGATCCAGCC) [23]. Amplified product was sequenced and homology searches were conducted by comparing sequences with those in public databases (NCBI) using the Basic Local Alignment Search Tool (BLAST) and EzBioCloud database (<http://www.ezbiocloud.net/>) [24]. Phylogenetic analyses were performed using MEGA software version 11, with sequence aligned against neighboring nucleotide sequences using CLUSTALW [25]. The phylogenetic tree was constructed using the neighbor-joining (NJ) method, and the topologies were evaluated through bootstrap sampling based on 1000 replicates.

2.5. Antimicrobial Testing Activity of *Streptomyces* sp. ACT158

The antibacterial activity of *Streptomyces* sp. ACT158 was evaluated using the agar diffusion method as described by Benhadj et al. [8]. Mycelium plugs (7 mm) deposited onto LB (Luria and Bertani) plates inoculated with bacterial indicator strains (Table S1) at an optical density of 0.04 and the activity was assessed over 3, 7, 10, 14, 17, and 21 days. Two culture media (ISP2) and Glycerol yeast extract agar (GYEA) were used to optimize bioactive molecule production. Similarly, the antifungal activity of ACT158 was screened using the agar plug and double-layer methods. In the latter, ACT158 was incubated on ISP2 plates for 10 days, followed by overlaying with ISP2 agar inoculated with target organism. Inhibition zones were measured after 48 hours and 10 days at 30°C for yeast and molds respectively.

2.6. Genome sequencing, Assembly, Gene Prediction and Functional Annotation

ACT158 was cultured in ISP2 solid medium were incubated at 28°C for 4 days. After incubation, DNA was extracted as described previously [18]. The genomic DNA of ACT158 strain was fragmented to 150 bp, and libraries were constructed and sequenced using by paired-end strategy with Illumina Mi-seq technology. The raw data were quality-controlled using the FastQC v. 0.11.9 [26], and reads were used assembled de novo using the hybrid spades program (SPAdes v. 3.13.0) [27].

The genome of *Streptomyces* sp. ACT158 was comprehensively annotated using multiple bioinformatics tools and databases. Gene prediction and functional annotation were encoded using the NCBI Prokaryotic Genome Annotation Pipeline [28] and rapid annotations using subsystems technology (RAST) (<http://rast.nmpdr.org/>) [29,30]. Orthologous genes were annotated using EggNOG mapper (v.2.1.12) to infer functional and structural insights. Additionally, metabolic pathways were reconstructed using GhostKOALA, integrated with KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathway data [31]. The proteomes of *Streptomyces* sp. ACT158 was subjected to automated annotation and assignment to CAZymes [32] using the dbCAN3 meta server and HMMdb v12.0, identified by at least two tools within the server including HMMER, dbCAN, DIAMOND, CAZy and dbCAN-sub. The biosynthetic potential of the ACT158 was explored through antiSMASH (v.7) for functional annotation and mining of natural products biosynthetic gene clusters [33]. The graphical representation of the genome was generated using Proksee [34].

2.7. Phylogenomics, and Comparative Genome Analysis

The genome sequence data were uploaded to the Type (Strain) Genome Server (TYGS) (<https://tygs.dsmz.de>), for a whole genome-based taxonomic analysis [35]. The resulting intergenomic distances were used to infer a balanced tree with branch support via FASTME 2.1.6.1 including SPR postprocessing (Lefort et al. 2015) and branch support was inferred from 100 pseudo-bootstrap replicates each. The Genome-to-Genome Distance Calculator (GGDC) was employed for species delineation (<http://ggdc.dsmz.de/home.php>) [36] and the estimate DDH resulted from a generalized linear model (GLM). The recommended cutoff value for species delimitation using GGDC was 70% similarity, as examined using Formula 2. Additionally, average nucleotide identity (ANI) values were calculated using the BLAST-based OrthoANI tool [37]. Comparative genome analysis of COGs in *Streptomyces* sp. ACT158 and the most closely relative species including *S. cavourensis* DSM41795^T (GCA_006788935.1), *S. cavourensis* JCM4298^T (GCA_014649215.1), *S. rhizosphaericola* 1AS2c^T (GCA_004794175.1), and *S. nanshensis* SCSIO10429^T (GCA_001751255.1) were performed using a BLAST-based analysis with OrthoVenn v.3) [38] under default parameters. Subset genes, such as species group shared and unique subsets of genes within individual genomes, were identified by clustering the results from the core and pan-genome calculations.

3. Results

3.1. Phenotypical Characterization of ACT158

The micro-morphological features of *Streptomyces* sp. ACT158 were observed after cultivation on ISP2 medium at 30°C. The strain is Gram-positive bacterium characterized by long filaments capable of producing aerial mycelia and spores. The strain exhibited good growth on ISP1, ISP2, ISP4, and ISP6 media, moderate growth on ISP3 and ISP7, and displayed various mycelium colors, including pale yellow, beige, and brown. Diffusible melanoid pigments were detected on all tested media except ISP3 and ISP4 (Table S1). The strain grew well at 40°C but not at 4°C, with an optimal growth temperature of 30°C, at salt concentration up to 5% and could grow across a pH range (3-10). *Streptomyces* sp. ACT158 present functional diversity, producing enzymes such as amylase, coagulase, gelatinase, citrate permease, nitrate reductase, cellulase, caseinase, and esterase. Hemolytic and catalase activities were also observed. The strain utilized mannitol, glucose, sorbitol,

sucrose, and melibiose as carbon sources, with accompanying acid production. However, it could not metabolize arabinose, rhamnose, or inositol.

3.2. MALDITOF and 16SrRNA Based Analysis

The strain was subjected to identification using MALDITOF-MS and raw mass spectrometry profiles were clustered to validate the accuracy of the MALDI Biotyper identification. The results showed that ACT158 producing reliable results affiliated to *Streptomyces cavourensis* with log score of 2.29 ± 0.02 . Representative spectra profiles of ACT158 are shown in Figure S1. The phylogenetic analysis of strain ACT158 was conducted based on 16S rRNA gene sequencing. Using EzBioCloud database, nearly the complete sequence of the 16S rDNA gene (1487 bp) was identified. The sequence analysis revealed a 100% similarity with the type strain of *S. cavourensis* NBRC 13026^T and 99.38% with *S. bacillaris* NBRC 13487^T (Figure 1).

3.3. Genome Assembly, Annotation and Functional Analysis

Genome sequence assembly and general genomic features of ACT158 are presented in Table 1 and Figure 2. The circular chromosome was found to be 6,858,072 bp with a GC content of 71.1%. The annotated genome included 5,122 protein-coding genes (CDSs), with a coding ratio of 71.1 % and 639 putative pseudogenes. The chromosome included 3 rRNAs, 54 transfer RNAs genes and eight clustered regularly interspaced short palindromic repeats-CRISPR-associated (CRISPR-Cas) system.

A comprehensive genomic analysis of *Streptomyces* sp. ACT158 revealing its extensive metabolic capabilities and functional diversity. Based on KEGG pathway analysis (Figure 3). Based on KEGG analysis, 2410 genes, or 35.3 % of all CDSs, were mapped to 41 KEGG pathways highlighted the strain's involvement in key metabolic, including amino acid metabolism, carbohydrate metabolism, secondary metabolite biosynthesis, energy production, nucleotide metabolism, and environmental information processing. These pathways underline its metabolic adaptability and its potential for bioactive compound production.




Figure 1. The phylogenetic relationships based on 16S rRNA gene sequences between Streptomyces sp. ACT158 and other related taxa generated by Neighbour-Joining. Bootstrap values (expressed as percentages of 1000 replications) greater than 50 % are shown. Bar, 0.005 substitutions per nucleotide position.

Table 1. General features of Streptomyces sp. ACT158 draft genome sequence.

| Characteristics | Values |
|----------------------------|-----------|
| Total Length (bp) | 6,858,072 |
| Number of coding sequences | 6831 |
| GC Content (%) | 71.8% |
| N50 | 8,070 |
| Gap Ratio (%) | 0.0% |
| No. of CDSs | 5,122 |
| No. of rRNA | 3 |
| No. of tRNA | 54 |
| No. of CRISPRs | 8 |
| Coding Ratio (%) | 70.1% |

In addition, COG (Clusters of Orthologous Groups) functional classification provided insights into gene clusters associated with 23 functional groups based on the COG codification. Major contributions included genes related to A (RNA processing and modification), B (Chromatin structure and dynamics), C (Energy production and conversion), D (Cell cycle control and mitosis), and E (Amino acid transport and metabolism), with the latter showing the highest representation (966 genes). Other significant categories included carbohydrate transport and metabolism (687 genes), transcription (987 genes), and energy production and conversion (617 genes). Additional

classifications, such as cell wall/membrane biogenesis (285 genes), signal transduction, and secondary metabolite biosynthesis, further highlight the strain's capacity for complex metabolic and regulatory processes. Rapid Annotations using Subsystems Technology (RAST) offered further details on functional diversity, with 275 subsystems for carbohydrate metabolism, more than 410 subsystems for protein, amino acids and derivatives metabolism, and 44 subsystems related to membrane transport. Stress response genes and pathways for DNA repair and secondary metabolite production were also identified, showcasing its ecological resilience and industrial potential. About (196) carbohydrate-active enzymes (CAZymes) was annotated, including 90 glycoside hydrolases (GHs) including amylases (GH13, 15), chitinase (GH18, 19, 23), chitosanase (GH5), cellulase (GH6), 39 glycosyl transferases (GTs), 28 auxiliary activity enzymes (AAs), and 22 carbohydrate-binding modules (CBMs). This diversity indicates the strain's ability to degrade complex carbohydrates and its role in polysaccharide breakdown, which is crucial for natural product biosynthesis and biotechnological applications.




Figure 2. Circular chromosome map of the whole genome of *Streptomyces* sp. ACT158 generated through Proksee (<https://proksee.ca>).




Figure 3. Distribution of subsystem categories found in the genome of *Streptomyces* sp. ACTS158, obtained through the genome annotation on KEGG, EGGNOG, RAST and dbcan.3.4 Similarity of Whole Genomes.

The phylogenomic analysis of strain ACT158 was conducted using genome sequences from related *Streptomyces* taxa, as shown in Figure 4. The phylogenomic tree, inferred with FastME based on GBDP distances, revealed the clustering of ACT158 with *Streptomyces cavourensis* strains JCM 4298 and DSM 41796, supported by high bootstrap values (>60%) and an average branch support of 89.1% (Figure 4A). Genomic similarity assessments were evaluated using average nucleotide identity (ANI) and in silico DNA–DNA hybridization (DDH), with results summarized in Figure 4B. ANI analysis revealed 99.2% similarity between ACT158 and *S. cavourensis* DSM 41795[†] and *S. cavourensis* JCM 4298[†] (Figure 4C). Similarly, DDH analysis revealed 90.4% and 90.3% similarity between ACT158 and both reference strains. These values exceed the species delineation thresholds of ≥95% for ANI and ≥70% for in silico DDH, confirming the taxonomic identification of ACT158. The heat map of the similarity matrix further supported these findings, clearly differentiating ACT158 from other *Streptomyces* species and reinforcing its identification as a strain of *S. cavourensis*.

3.5. Comparative Genome Analysis

Comparative genomic analysis of ACT158 and four *Streptomyces*-type strains, revealed substantial gene family conservation (Figure 5). A significant proportion, 73.03% (4955 out of 6784), of identified gene families were shared among all five species. Among these strains, *S. cavourensis* DSM 41795 and *S. cavourensis* JCM4298 exhibited the highest number of gene families (6384 and 6849, respectively), whereas *Streptomyces* sp. ACT158 presented 5792 gene families. Notably, a high degree of gene family conservation was observed within the *S. cavourensis* species complex, with 90.8% (5774 out of 6361) of identified gene families (Figure 5). Gene Ontology (GO) enrichment analysis of significantly enriched, commonly shared gene families across all strains revealed associations with fundamental biological processes, including metabolic processes (GO:0008152), biological processes (GO:0008150), cellular metabolic processes (GO:0044237), and nitrogen compound metabolic processes (GO:0006807) (Table S2).

3.6. Antimicrobial Activity of ACT158

The antimicrobial activity of *Streptomyces* sp. ACT158 was evaluated against a panel of bacterial and fungal strains (Figures 6). The strain exhibited notable antibacterial activity against all tested bacterial indicators except *Pseudomonas aeruginosa* clinical isolates. The inhibition zones varied depending on the incubation period, indicator strain, and production medium. On GYEA medium, the highest activity against bacteria was observed on day 3, with *Staphylococcus aureus* exhibiting a 25 mm inhibition zone. By day 7, the activity was more pronounced against *Salmonella typhimurium* ATCC 14028 in ISP2 medium, measuring 19mm. Overall, *Streptomyces* ACT158 exhibited potent antagonistic activity against both Gram-positive and Gram-negative bacteria, with GYEA appearing as the most suitable medium for producing antibacterial bioactive molecules.

The results of antifungal screening indicated inhibition of all tested yeasts except *Candida parapsilosis* LCP, with inhibition zones ranging from 11.5 mm to 36 mm in diameter. For filamentous fungi, the antifungal activity was particularly notable. The strain displayed high inhibition against *Penicillium chrysogenum* (43.5 mm) (Figure 6),




Figure 4. Phylogenomic tree based on genome sequences of ACT158, and other related taxa inferred with FastME 2.1.6.1 (Lefort et al. 2015) from GBDP distances. The branch lengths are scaled in terms of GBDP distance formula d5. The numbers above branches are GBDP pseudo-bootstrap support values > 60 % from 100 replications, with an average branch support of 89.1 %. The tree was rooted at the midpoint (Farris 1972) (A), Digital DNA-DNA hybridization (dDDH (B), calculated using the Genome-to-Genome Distance Calculator 2.1 on the DSMZ website) and Average nucleotide identity (ANI (C) calculated using the BLAST-based OrthoANI) heatmaps among closely related *Streptomyces* species.




Figure 5. Ortholog clusters analysis between *Streptomyces* sp.ACT158 and their closely related *Streptomyces* species A. Ortholog clusters count, B. Venn diagram represents distribution of shared and unique gene clusters among ACT158, *S. cavourensis* DSM41795 and *S. cavourensis* JCM4298.

Pecilomyces variotii (25.5–39.5 mm), and *Rhizopus oryzae* (26–42 mm). Antifungal activity started as early as day 3, with pronounced effects against *Penicillium* and other filamentous fungi. Both ISP2 and GYEA media supported antifungal metabolite production, although GYEA was slightly more suitable. The graphical representation further confirms the medium-dependent variation in antimicrobial activity across tested strains and incubation times. These findings highlight the versatility of *Streptomyces* sp. ACT158 in producing bioactive compounds with broad-spectrum antimicrobial properties, underscoring its potential for biotechnological and pharmaceutical applications.




Figure 6. Antimicrobial activity (mm) of *Streptomyces* sp. ACT158 on GYEA and ISP2 after 3, 7 and 10 days of incubation (A), Antifungal activity of *Streptomyces* sp. ActiF450 on the growth of different test organisms (B). The active strain ACT158 was inoculated as a spot in the center of ISP2 plates at 30 °C for 7 days. After, the plates were then covered by 10 ml of GYEA pre-piously inoculated with target fungi (1: *Rhodotorula mucilaginosa*, 2: *Penicillium chrysogenum* , 3: *Rhizopus oryzae*).

3.7. Analysis of Secondary Metabolic Biosynthetic Gene Clusters

The genome of *Streptomyces* sp. ACT158 was analyzed using the antiSMASH platform, revealing the presence of 32 predicted secondary metabolic biosynthetic gene clusters (BGCs) (Table 2). These clusters included ribosomally synthesized and post-translationally modified peptides (RiPPs), lanthipeptide class II, III, nonribosomal peptide synthetases (NRPS), siderophores, butyrolactones, ectoine, and terpenes. Several of these BGCs demonstrated high similarity to known biosynthetic gene clusters, suggesting their potential role in producing bioactive compounds. Among the identified BGCs, noteworthy clusters included an NRPS-T1PKS cluster with 100% similarity to the naringenin biosynthetic gene cluster (BGC0001310) and an NRPS-T3PKS cluster identical to alkylresorcinol (BGC0000282). Additionally, the NRPS clusters exhibited varying similarities to well-characterized compounds such as jadomycin (42%), valinomycin/montanastatin (73%), and ectoine (75%) (Figure 8). Other significant hits included siderophore desferrioxamine B with 100% similarity and terpene geosmine, also with 100% similarity. Interestingly, the analysis also identified BGCs with

lower similarity but linked to important bioactive molecules. These included an NRPS cluster with 50% similarity to the heat-stable antifungal factor (BGC0002365), a butyrolactone cluster with 29% similarity to showdomycin (BGC0001778), and a RiPP cluster with 22% similarity to lactazole (BGC0000606). Additionally, clusters for antibiotics like kinamycin (13%), steffimycin D (16%), and bafilomycin B1 (27%) were detected, suggesting that ACT158 may encode novel derivatives of these potent compounds, further underscores the strain’s capability to produce complex secondary metabolites (Figure 7).

4. Discussion

Actinomycetes, particularly *Streptomyces* species, are well-documented for their ability to produce a vast array of antibiotics and other bioactive compounds [39]. These microorganisms, found in diverse ecological niches, have evolved to produce an extensive array of secondary metabolites that are of considerable interest in the pharmaceutical, agricultural, and industrial sectors [12]. This metabolic diversity is closely tied to their ecological role in nutrient cycling and organic matter degradation [40,41]. Wetlands, often considered one of the most biodiverse ecosystems, are home to a range of microorganisms that play critical roles in biogeochemical cycles [17]. The environmental conditions in these ecosystems, such as fluctuating oxygen availability, nutrient concentration, and other factors, impose selective pressures on the microbial community [18]. This dynamic environment can lead to the emergence of microorganisms capable of producing a wide range of bioactive secondary metabolites, including enzymes and antimicrobial compounds [16].

In this study, a strain *Streptomyces* sp. ACT158, isolated from such a unique and typical environment (Fetzara Lake), could unlock specific biochemical pathways that enable the strain to thrive in these conditions. Phenotypic characterization revealed ACT158’s ability to grow on multiple media types, including ISP1, ISP2, ISP4, and ISP6, while producing aerial mycelium and diffusible pigments. The pigmentation in actinomycetes is a hallmark of stress response pathways often linked to secondary metabolite biosynthesis [42]. Additionally, the strain’s capacity to produce extracellular enzymes such as amylase, cellulase, and protease highlights its functional versatility and genomic organization [43]. These enzymes not only facilitate nutrient acquisition in diverse environments but also provide precursors for secondary metabolite synthesis [45].

Table 2. Putative secondary metabolites gene clusters in *Streptomyces* sp. ACT158 predicted by antiSMASH.

| Type | MIBiG accession | Known cluster blast (Biosynthetic gene) | Similarity | Potential activity |
|------------|--------------------|--|------------|-----------------------|
| NRPS-T1PKS | BGC0001310 | naringenin | 100% | Antifungal, antiviral |
| NRPS-T1PKS | BGC0002591 | aurachin C | 20% | Antibacterial |
| NRPS-T1PKS | BGC0000236 | kinamycin | 13% | Antitumor |
| NRPS-T1PKS | BGC0000273 | steffimycin D | 16% | Antitumor |
| NRPS-T1PKS | BGC0000028 | | | Antibacterial, |
| | | bafilomycin B1 | 27% | antitumor |
| NRPS-T1PKS | BGC0001477 | lydicamycin | 32% | Antibacterial |
| NRPS-T1PKS | BGC0001348 | JBIR-100 | 38% | Antimicrobial |
| NRPS-T1PKS | BGC0001700 | niphimycins C-E | 29% | Antimicrobial |
| NRPS-T2PKS | BGC0000234 | jadomycin | 42% | Antimicrobial |
| NRPS-T3PKS | BGC0000282 | alkylresorcinol | 100% | Antibacterial |

| | | | | |
|---------------|------------|-------------------------------|------|--------------------|
| | BGC0002001 | | | Antimicrobial, |
| NRPS | | crochelin | 16% | antitumor |
| NRPS | BGC0001845 | alpiniamide | 88% | Antimicrobial |
| NRPS | BGC0000453 | valinomycin/montanastatin | 73% | Antimicrobial |
| NRPS | BGC0000325 | coelichelin | 63% | / |
| NRPS | BGC0001368 | JBIR-126 | 7% | Antimicrobial |
| NRPS | BGC0000368 | griseobactin | 30% | Antibacterial |
| NRPS | BGC0002441 | o-dialkylbenzene 1 | 12% | / |
| NRPS | BGC0002295 | minimycin | 40% | Antimicrobial |
| NRPS | BGC0002365 | heat-stable antifungal factor | 50% | Antifungal |
| NRPS | BGC0000375 | | | Antibacterial, |
| | | indigoidine | 40% | antioxydant |
| RiPP | BGC0000583 | linaridin | 20% | Antibacterial |
| RiPP | BGC0000496 | AmfS | 60% | Antimicrobial |
| | BGC0000606 | | | Antimicrobial, |
| RiPP | | lactazole | 22% | antitumor |
| RiPP | BGC0001634 | keywimysin | 80% | Antibacterial |
| | BGC0000941 | | | Antimicrobial,Iron |
| Siderophore | | desferrioxamin B | 100% | Chelation |
| butyrolactone | BGC0001778 | showdomycin | 29% | Antimicrobial |
| butyrolactone | BGC0000038 | coelimycin | 8% | Antibacterial |
| Ectoine | BGC0000858 | ectoine | 75% | Osmolyte |
| Terpene | BGC0001181 | geosmine | 100% | / |
| Terpene | BGC0000664 | isorenieratene | 42% | / |
| Terpene | BGC0000663 | hopene | 46% | |




Figure 7. AntiSMASH predicted biosynthetic gene clusters and their predicted core structures from *Streptomyces* sp. ACT158 genome.

Such metabolic plasticity enhances the strain's adaptability, crucial traits for industrial large-scale processes requiring stable microbial performance under variable conditions [46]. Cellulases are widely used in the biofuel industry for the conversion of lignocellulosic biomass into fermentable sugars, a crucial step in the production of bioethanol [47]. In the food industry, amylases are employed for starch hydrolysis, which is fundamental in brewing, baking, and other food production processes [48]. Similarly, proteases are crucial in detergent manufacturing, food processing, leather industry, pharmaceuticals and waste management [49].

The phylogenomic analysis of strain ACT158 confirms its classification within the *S. cavourensis* species. Phylogenetic reconstruction using genome sequences from related taxa revealed a close relationship between ACT158 and *S. cavourensis*. Genomic similarity assessments using ANI and dDDH further corroborated this identification. *S. cavourensis* has been previously identified in a wide range of ecological niches, including marine ecosystems, agricultural soils and plants [50,51]. This broad habitat distribution highlights its exceptional adaptability to diverse environmental conditions and its ecological role in nutrient recycling and organic matter degradation. To further understand the genomic characteristics of *Streptomyces* sp. ACT158, it is essential to consider the importance of genomic relatedness indices in species classification. Modern methods such as Average Amino Acid Identity (AAI), Digital DNA-DNA Hybridization (dDDH), and Average Nucleotide Identity (ANI) have become the gold standard for accurately determining the species and resolved the taxonomic status of complex taxon [52], particularly within the genus *Streptomyces* [53]. These methods provide a reliable framework for distinguishing between species and for identifying new strains with unique properties in cases where traditional phenotypic methods may not provide sufficient resolution for species identification [54].

The genome of ACT158, with a size of approximately 6.8 Mb and a GC content of 71.1%, is typical of the *Streptomyces* genus, which is notable among bacteria for their large linear chromosomes with terminal inverted repeats and range in size from 6 to 12 Mb, encoding between 5,300 and 11,000 proteins [55]. The genome annotation revealed a wealth of protein-coding genes associated with amino acid metabolism, carbohydrate transport, energy production, secondary metabolite biosynthesis and other biologically relevant compounds. Functional annotation of the genome provides insights into the roles of individual genes and their contributions to the overall metabolic network of the organism [56]. This process involves assigning putative functions to genes based on sequence similarity to entries in databases like KEGG, dbcan, and COG [57].

Enzymes are fundamental to metabolic processes, enabling the organism to adapt to diverse environmental conditions and produce valuable secondary metabolites [58]. The ACT158 genome typically contains a rich repertoire of genes encoding enzymes involved in primary and secondary metabolism. The prediction of genes encoding extracellular hydrolytic enzymes, such as cellulases, amylases, and proteases, corroborates the strain's enzymatic activities observed in phenotypic assays. For example, prediction of amylase, kitinase and cellulase involved in carbohydrate degradation, also the identification of proteases that play critical roles in nutrient acquisition, and stress response., which are of interest for industrial applications like biofuel production and bioremediation and other applications [48,49].

In addition, the genome of *Streptomyces* sp. ACT158 may encode lipases, and esterases, which are widely used in industries ranging from food and detergents to pharmaceuticals [59]. The presence of genes encoding oxidoreductases, such as peroxidases, is particularly noteworthy, as these enzymes are essential for the degradation of complex organic and aromatic compounds [60]. This capability makes *Streptomyces* sp. ACT158 a strong candidate for applications in environmental biotechnology, such as waste management and pollutant degradation.

A key outcome of genomic annotation is the identification of genes associated with stress response and adaptation to environmental conditions [61]. For *Streptomyces* sp. ACT158, genes encoding heat-shock proteins and oxidative stress enzymes are identified, reflecting the strain's ability to survive in the dynamic and challenging conditions of wetlands. Genome analysis of the endophyte *Streptomyces* sp. KLBMP 5084 have highlighted their capacity to adapt to environmental stresses by encoding superoxide dismutases, peroxidases, catalases, and proteins involved in heavy metal resistance, as well as cold and heat shock proteins [62]. Similarly, a genomic investigation of *Streptomyces* sp. H-KF8 identified numerous genetic determinants associated with heavy metal resistance (49 genes), oxidative stress (69 genes), and antibiotic resistance (97 genes) [63]. Additionally, genes related to heavy metal resistance and osmotic stress suggesting a capacity for bioremediation in contaminated environments. The annotation also uncovers genes involved in regulation and cell signaling networks, which play a crucial role in secondary metabolite production and environmental adaptation [61]. Functional analysis reveals a well-developed primary metabolism that supports the biosynthesis of precursors for secondary metabolites: amino acid derivatives, glycolysis, TCA cycle and the pentose phosphate pathways provide energy and biosynthetic intermediates required for the production of polyketides and nonribosomal peptides [64].

The identification of enzyme systems involved in xenobiotic degradation further underscores the strain's environmental adaptability. These systems often include monooxygenases, dioxygenases, and hydrolases that catalyze the breakdown of toxic compounds [65]. These predictions align with the ecological niche of *Streptomyces* sp. ACT158, suggesting that the strain has adapted to thrive in wetlands, which are often rich in organic matter and potential pollutants and may reveal enzymes with unexplored catalytic activities, opening new avenues for biotechnological innovation. Experimental validation of predicted enzymes is crucial to confirm their functions and assess their industrial potential. For *Streptomyces* sp. ACT158, validation studies can focus on key enzymes identified in biosynthetic gene clusters (BGCs) or those implicated in the degradation of complex polymers. The integration of enzyme prediction with other omics approaches, such as

transcriptomics and proteomics, enhances the understanding of enzyme functionality under different conditions [66]. For example, transcriptomic data can reveal which enzyme-encoding genes are actively expressed in response to specific environmental stimuli, such as nutrient availability or stress factors [67].

The antimicrobial potential of *Streptomyces* sp. ACT158 further enhances its biotechnological appeal. The strain was found to exhibit broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria (*Staphylococcus aureus*, *Bacillus subtilis*, *Micrococcus luteus*, *Klebsiella pneumoniae* and *Salmonella Typhimurium*), as well as fungal pathogens, such as *Aspergillus* and *Candida*. Historically, *Streptomyces* species have been a valuable source of antibiotics, producing around 100,000 compounds, which account for 70–80% of all natural bioactive products with pharmacological or agrochemical such as streptomycin, tetracycline, and erythromycin [3]. The broad-spectrum antimicrobial activity displayed by *Streptomyces* sp. ACT158 suggests of the production of different antimicrobial agents. *Streptomyces* produce a variety of natural products with high structural diversity, including macrolides, tetracyclines, aminoglycosides, glycopeptides, ansamycins, and terpenes [68].

The antimicrobial activity was particularly pronounced in GYEA compared to ISP2 media, where inhibition zones against key pathogens reached up to 25 mm. The strain also demonstrated potent antifungal properties, effectively suppressing the growth of yeast and filamentous fungi such as *Candida* spp., *Aspergillus* spp., *Penicillium* spp., *Paecilomyces* spp. and *Rhizopus*. The rapid onset of antifungal activity, observed within three days, suggests a highly efficient secondary metabolite production mechanism. The production of antimicrobial compounds by *Streptomyces* strains is strongly influenced by culture conditions, including media composition, incubation time, and the organisms used in testing [69]. Carbon sources, in particular, play a pivotal role in regulating antibiotic synthesis. Research has shown that preferred carbon sources can suppress secondary metabolism, which may reduce antibiotic production (Sánchez et al. 2010) [70]. This regulation could explain the varying inhibition patterns observed in *Streptomyces* sp. ACT158 antagonistic assays when tested in different media, highlighting the importance of tailoring environmental conditions to enhance their antimicrobial activity. The strain *S. cavourensis* NRRL 2740 has been identified as a producer of several bioactive compounds, including the antitumor agent chromomycin [71], the antifungal metabolite flavensomycin, and humidin [72]. Additionally, macrolide antibiotics such as bafilomycins (B1, C1, and D) and hygrobafilomycin, known for their potent antifungal properties, have been associated with *S. cavourensis* species [73].

Genomic analysis provided further insights into the strain's biosynthetic potential. AntiSMASH analysis predicted secondary metabolic biosynthetic gene clusters (BGCs), including those for polyketide synthases (PKS), nonribosomal peptide synthetases (NRPS) terpenoids, and other classes of bioactive compounds. The presence of multiple BGCs suggests that the strain is capable of producing a wide variety of bioactive compounds, which could be of significant interest for pharmaceutical and industrial applications. In addition, the presence of BGCs with low similarity to known clusters can uncover novel antibiotics, and other bioactive molecules with therapeutic potential.

Polyketides are a diverse class of secondary metabolites with notable pharmacological activities, including antibiotic, anticancer, and immunosuppressive properties [74]. Notably, one NRPS-T1PKS cluster displayed complete similarity to the biosynthetic gene cluster (BGC) of the flavonoid naringenin, while another NRPS-T3PKS cluster was associated with alkylresorcinol. Although naringenin is primarily known as a plant-derived metabolite, it has recently been identified in a few *Streptomyces* species [75]. Furthermore, its encoding gene cluster has also been detected in certain *Saccharotrix* and *Kitasatospora* species [76]. Several biological activities have been associated to these compounds, including antioxidant, antitumor, antiviral, antibacterial, antifungal and anti-inflammatory [77]. Additionally, Type II PKS clusters, associated with aromatic polyketides like jadomycin were detected. These clusters employ an iterative mechanism of chain elongation and cyclization, producing highly conjugated and planar structures typical of compounds with

antibacterial and anticancer properties [78]. The identification of Type III PKS clusters, which catalyze the condensation of acyl-CoA precursors without requiring a carrier protein, suggests the strain's ability to produce simple aromatic polyketides like chalcones and resorcinols, which often serve as precursors for complex natural products or exhibit independent bioactivities [79].

The genome annotation reveals the presence of several NRPS with a range of bioactive properties. Notable examples with high similarity $\geq 50\%$ include alpiniamide and valinomycin/montanastatin, all of which have significant potential [80–82]. Other compounds like griseobactin, minimycin, and heat-stable antifungal factor further demonstrate the strain's ability to produce a variety of peptides with diverse bioactivities including antibacterial, antifungal and anticancer activities. Beyond PKS, NRPS, and terpenoid clusters, the genome of *Streptomyces* sp. ACT158 includes BGCs for RiPPs and siderophores, which contribute to its metabolic versatility and potential bioactivity both antimicrobial and antitumor potential [83] (Hudson and Mitchell, 2018).

Comparative genomic analysis placed ACT158 within the *Streptomyces cavourensis* species complex, with ANI and DDH values supporting its taxonomic assignment. Despite its close relationship to other *S. cavourensis* strains, ACT158 harbors unique gene families, likely contributing to its specialized ecological adaptations and secondary metabolite production capabilities. These unique genetic features emphasize the significance of exploring underrepresented environments like wetlands for discovering actinomycetes with novel biosynthetic traits. Overall, *Streptomyces* sp. ACT158 exemplifies the potential of actinomycetes from unique ecological niches to address critical challenges in medicine and industry. Its phenotypic adaptability, metabolic diversity, and genomic insights indicate its suitability for developing novel bioactive compounds. Future research should prioritize isolating and characterizing the specific secondary metabolites produced by ACT158 to unlock its full biotechnological potential. In addition, optimizing fermentation conditions to enhance metabolite yield and exploring its environmental applications could pave the way for sustainable exploitation of this promising strain.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org: Figure S1: MALDI-TOF-MS identification of *Streptomyces* sp. ACT158. Table S1: Phenotypic characteristics and extracellular enzyme production of *Streptomyces* sp. ACT158 compared to the reference strain *S. cavourensis* NRBC 13026^T; Table S2: List of indicator microorganisms used in this study; Table S3: Distribution of subsystem categories found in the genome of *Streptomyces* sp. ACT158.

Author Contributions: MB: Conceptualization, Investigation, Methodology, Writing original draft and Validation; TM: Data curation, Formal analysis, Methodology, Software, Visualization Writing – review and editing; NZ: Writing – review and editing, Software, SR; Supervision, Writing – review and editing.

Funding: The authors declare that no funds, grants, or other support was received during the preparation of this manuscript.

Data Availability Statement: Further inquiries can be directed to the corresponding authors.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Rani, A; Saini, K. C; Bast, F; Mehariya, S; Bhatia, S. K; Lavecchia, R; & Zuorro, A. Microorganisms: a potential source of bioactive molecules for antioxidant applications. *Molecules*, **2021**. 26(4), 1142.
2. Selim, M. S. M; Abdelhamid, S. A; & Mohamed, S. S. Secondary metabolites and biodiversity of actinomycetes. *J. Gen. Eng. Biotechnol*, **2021**. 19(1), 72.
3. Alam, K; Mazumder, A; Sikdar, S; Zhao, Y. M; Hao, J; Song, C; ... & Li, A. *Streptomyces*: The biofactory of secondary metabolites. *Front Microbiol*, 2022. 13, 968053.
4. Komaki, H. Recent progress of reclassification of the genus *Streptomyces*. *Microorganisms*, **2023**. 11(4), 831.

5. Shepherdson, E. M; & Elliot, M. A. Cryptic specialized metabolites drive *Streptomyces* exploration and provide a competitive advantage during growth with other microbes. *Proc Nat Acad Sci*, **2022**. 119(40), e2211052119.
6. Benhadj, M; Gacemi-Kirane, D; Menasria, T; Guebla, K; & Ahmane, Z. Screening of rare actinomycetes isolated from natural wetland ecosystem (Fetzara Lake, northeastern Algeria) for hydrolytic enzymes and antimicrobial activities. *J. King Saud Univ. Sci*, **2019**. 31(4), 706-712.
7. Antonopoulos, V; Hernandez, M; Arias, M; Mavrakos, E; & Ball, A. The use of extracellular enzymes from *Streptomyces albus* ATCC 3005 for the bleaching of eucalyptus kraft pulp. *Appl. Microbiol. Biotechnol*, **2001**. 57, 92-97
8. Benhadj, M; Metrouh, R; Menasria, T; Gacemi-Kirane, D; Slim, F. Z; & Ranque, S. Broad-spectrum antimicrobial activity of wetland-derived *Streptomyces* sp. ActiF450. *EXCLI J*, **2020**. 19, 360.
9. LPSN (List of Prokaryotic names with Standing in Nomenclature) <https://lpsn.dsmz.de/genus/streptomyces> (accessed on 20 December 2024)
10. Zaatout, N; Al-Mustapha, A. I; Bouaziz, A; Ouchene, R; & Heikinheimo, A. Prevalence of AmpC, ESBL, and colistin resistance genes in Enterobacterales isolated from ready-to-eat food in Algeria. *Brazilian J. Microbiol*, **2023**. 54(3), 2205-2218.
11. Boukoucha, M; Menasria, T; & Bouguerra, N. Phenotypic characterization and genotypic subtyping of *Salmonella enterica* Serovars enteritidis and Gallinarum isolated from human and poultry-related samples. *Food. Biotechnol*, **2018**. 32(3), 206-221.
12. Menasria, T; Monteoliva-Sánchez, M; Benhadj, M; Benammar, L; Boukoucha, M; & Aguilera, M. Unraveling the enzymatic and antibacterial potential of rare halophilic actinomycetes from Algerian hypersaline wetland ecosystems. *J. Basic Microbiol*, **2022**. 62(10), 1202-1215.
13. Soldatou, S; Eldjárn, G. H; Ramsay, A; Van Der Hooft, J. J; Hughes, A. H; Rogers, S; & Duncan, K. R. Comparative metabologenomics analysis of polar actinomycetes. *Marine drugs*, **2021**. 19(2), 103
14. Kim, J. H; Lee, N; Hwang, S; Kim, W; Lee, Y; Cho. Discovery of novel secondary metabolites encoded in actinomycete genomes through coculture. *J. Indust. Microbiol. Biotechnol*, **2021**. 48(3-4), kuaa001.
15. Lee, N; Hwang, S; Kim, J; Cho, S; Palsson, B; & Cho, B. K. Mini review: Genome mining approaches for the identification of secondary metabolite biosynthetic gene clusters in *Streptomyces*. *Comput. Structural Biotechnol. J*, **2020**. 23 1548-1556.
16. Menasria, T; Monteoliva-Sánchez, M; Benammar, L; Benhadj, M; Ayachi, A; Hacène, H; ... & Aguilera, M. Culturable halophilic bacteria inhabiting Algerian saline ecosystems: a source of promising features and potentialities. *World J. Microbiol Biotechnol*, **2019**. 35, 1-16.
17. Menasria, T; Aguilera, M; Hocine, H; Benammar, L; Ayachi, A; Bachir, A. S; ... & Monteoliva-Sánchez, M. Diversity and bioprospecting of extremely halophilic archaea isolated from Algerian arid and semi-arid wetland ecosystems for halophilic-active hydrolytic enzymes. *Microbiol. Res*, **2018**. 207, 289-298.
18. Benhadj, M; Gacemi-Kirane, D; Toussaint, M; Hotel, L; Bontemps, C; Duval, R. E; ... & Leblond, P. Diversity and antimicrobial activities of *Streptomyces* isolates from Fetzara Lake, north eastern Algeria. *Annal Biol Clinique* **2018**. 76, No. 1).
19. Shirling, E. T; & Gottlieb, D. Methods for characterization of *Streptomyces* species. *Inter. J. Syst. Evol. Microbiol*, **1966**. 16(3), 313- 340.
20. Gordon, R. E; Barnett, D. A; Handerhan, J. E; & Pang, C. H. N. *Nocardia coeliaca*, *Nocardia autotrophica*, and the nocardin strain. *International Journal of Systematic and Evolutionary Microbiology*, **1974**. 24(1), 54-63.
21. Cassagne C., Normand A.C., Bonzon L., L'Ollivier C., Gautier M., Jeddi F., Ranque S., & Piarroux R. Routine identification and mixed species detection in 6,192 clinical yeast isolates. *Med Mycol*, **2016**. 54(3):256-65.
22. Kieser, T. B. M. J; Bibb, M. J; Buttner, M. J; Chater, K. F; & Hopwood, D. A. Practical *Streptomyces*. *Genetics*, **2000**. 59.
23. Weisburg, W. G; Barns, S. M; Pelletier, D. A; & Lane, D. J. 16S ribosomal DNA amplification for phylogenetic study. *J Bacteriol*, **1991**. 173(2), 697-703.
24. Yoon, S. H; Ha, S. M; Lim, J; Kwon, S; & Chun, J. A large-scale evaluation of algorithms to calculate average nucleotide identity. *Antonie Van Leeuwenhoek*, **2017**. 110, 1281-1286.

25. Larkin, M. A; Blackshields, G; Brown, N. P; Chenna, R; McGettigan, P. A; McWilliam, H et al. Clustal W and Clustal X version 2.0. *Bioinformatics*, **2007**. 23(21), 2947-2948.
26. Andrews, S. *FastQC: a quality control tool for high throughput sequence data*. **2010**.
27. Antipov, D; Korobeynikov, A; McLean, J. S; & Pevzner, P. A. hybridSPAdes: an algorithm for hybrid assembly of short and long reads. *Bioinformatics*, **2016**. 32(7), 1009- 1015.
28. Tatusova, T; DiCuccio, M; Badretdin, A; Chetvernin, V; Nawrocki, E. P; Zaslavsky, L; ... & Ostell, J. NCBI prokaryotic genome annotation pipeline. *Nucleic Acids Res*, **2016**. 44(14), 6614-6624
29. Aziz, R. K; Bartels, D; Best, A. A; DeJongh, M; Disz, T; Edwards, R. A; ... & Zagnitko, O. The RAST Server: rapid annotations using subsystems technology. *BMC genomics*, **2008**. 9, 1-15.
30. Overbeek, R; Olson, R; Pusch, G. D; Olsen, G. J; Davis, J. J; Disz, T; ... & Stevens, R. The SEED and the Rapid Annotation of microbial genomes using Subsystems Technology (RAST). *Nucleic Acids Res*, **2014**. 42(D1), D206-D214.
31. Kanehisa, M; Sato, Y; & Morishima, K. BlastKOALA and GhostKOALA. KEGG tools for functional characterization of genome and metagenome sequences. *J. Mol Biol*, **2016**. 428(4), 726-731.
32. Lombard, V; Golaconda Ramulu, H; Drula, E; Coutinho, P. M; & Henrissat, B. The carbohydrate-active enzymes database (CAZy) in 2013. *Nucleic Acids Res*, **2014**. 42(D1), D490-D495.
33. Blin, K; Shaw, S; Augustijn, H. E; Reitz, Z. L; Biermann, F; Alanjary, M; ... & Weber, T. antiSMASH 7.0: new and improved predictions for detection, regulation, chemical structures and visualisation. *Nucleic Acids Res*, **2023**. 51(W1), W46-W50.
34. Grant, J. R; Enns, E; Marinier, E; Mandal, A; Herman, E. K; Chen, C. Y; ... & Stothard, P. Proksee: in-depth characterization and visualization of bacterial genomes. *Nucleic Acids Res*, **2023**. 51(W1), W484-W492
35. Meier-Kolthoff, J. P; & Göker, M. TYGS is an automated high-throughput platform for state-of-the-art genome-based taxonomy. *Nature communications*, **2019**. 10(1), 2182.
36. Meier-Kolthoff, J. P; Auch, A. F; Klenk, H. P; & Göker, M. Genome sequence-based species delimitation with confidence intervals and improved distance functions. *BMC bioinformatics*, **2013**. 14, 1-14.
37. Yoon, S. H; Ha, S. M; Lim, J; Kwon, S; & Chun, J. A large-scale evaluation of algorithms to calculate average nucleotide identity. *Antonie Van Leeuwenhoek*, **2017**. 110, 1281-1286.
38. Sun, J; Lu, F; Luo, Y; Bie, L; Xu, L; & Wang, Y. OrthoVenn3: an integrated platform for exploring and visualizing orthologous data across genomes. *Nucleic Acids Res*, **2023**. 51(W1), W397-W403.
39. Del Carratore, F; Hanko, E. K; Breitling, R; & Takano, E. Biotechnological application of *Streptomyces* for the production of clinical drugs and other bioactive molecules. *Curr Opin Biotechnol*, **2022**. 77, 102762.
40. Ouchene, R; Zaatout, N; & Suzuki, M. T. An Overview on Nocardiosis Species Originating From North African Biotopes as a Promising Source of Bioactive Compounds and In Silico Genome Mining Analysis of Three Sequenced Genomes. *J Basic Microbiol*, **2024**. 64(9), e2400046.
41. Benammar, L; Menasria, T; & Dibi, A. R. Deciphering the geochemical influences on bacterial diversity and communities among two Algerian hot springs. *Environ Sci Poll Res*, **2024**. 31(32), 44848-44862.
42. Sarmiento-Tovar, A. A; Silva, L; Sanchez-Suarez, J; & Diaz, L. *Streptomyces*-derived bioactive pigments: ecofriendly source of bioactive compounds. *Coatings*, **2022**. 12(12), 1858.
43. Bentley, S. D; Chater, K. F; Cerdeño-Tárraga, A. M; Challis, G. L; Thomson, N. R; James, K. D; ... & Hopwood, D. A. Complete genome sequence of the model actinomycete *Streptomyces coelicolor* A3. *Nature*, **2002**. 417(6885), 141-147.
44. Ouchene, R; Intertaglia, L; Zaatout, N; Kecha, M; & Suzuki, M. T. Selective isolation, antimicrobial screening and phylogenetic diversity of marine actinomycetes derived from the Coast of Bejaia City (Algeria), a polluted and microbiologically unexplored environment. *J. Appl. Microbiol*, **2022** 132(4), 2870-2882.
45. Dekak, A; Menasria, T; Benhizia, Y; & Chenchouni, H. Endophytic passenger bacteria associated with *Genista cinerea* nodules growing in North African drylands. *Rhizosphere*, **2020**. 14, 100205.
46. Abdelgalil, S. A; Soliman, N. A; Abo-Zaid, G. A; & Abdel-Fattah, Y. R. Bioprocessing strategies for cost-effective large-scale production of bacterial laccase from *Lysinibacillus macroides* LSO using bio-waste. *Inter. J. Environ. Sci. Technol*, **2020**. 1-20.

47. Singhania, R. R; Ruiz, H. A; Awasthi, M. K; Dong, C. D; Chen, C. W; & Patel, A. K. Challenges in cellulase bioprocess for biofuel applications. *Renewable Sustain Ener Rev*, **2021**. 151, 111622
48. Farooq, M. A; Ali, S; Hassan, A; Tahir, H. M; Mumtaz, S; & Mumtaz, S. Biosynthesis and industrial applications of α -amylase: A review. *Arch Microbiol*, **2021**. 203, 1281-1292.
49. Naveed, M; Nadeem, F; Mehmood, T; Bilal, M; Anwar, Z; & Amjad, F. Protease—a versatile and ecofriendly biocatalyst with multi-industrial applications: an updated review. *Catalysis Lett*, **2021**. 151, 307-323.
50. Vu, H. N. T; Nguyen, D. T; Nguyen, H. Q; Chu, H. H; Chu, S. K; Chau, M. V; & Phi, Q. T. Antimicrobial and cytotoxic properties of bioactive metabolites produced by *Streptomyces cavourensis* YBQ59 isolated from *Cinnamomum cassia* Prels in Yen Bai Province of Vietnam. *Curr Microbiol*, **2018**. 75, 1247-1255.
51. Wibowo, J. T; Kellermann, M. Y; Köck, M; Putra, M. Y; Murniasih, T; Mohr, K. I; .. & Schupp, P. J. Anti-infective and antiviral activity of valinomycin and its analogues from a sea cucumber-associated bacterium, *Streptomyces* sp. SV 21. *Marine drugs*, **2021**. 19(2), 81.
52. Riesco, R; & Trujillo, M. E. Update on the proposed minimal standards for the use of genome data for the taxonomy of prokaryotes. *Inter J Syst Evol Microbiol*, **2024**. 74(3), 006300
53. Mispelaere, M; De Rop, A. S; Hermans, C; De Maeseneire, S. L; Soetaert, W. K; De Mol, M. L; & Hulpiau, P. Whole genome-based comparative analysis of the genus *Streptomyces* reveals many misclassifications. *Appl Microbiol Biotechnol*, **2024**. 108(1), 453.
54. Mahato, N. K; Gupta, V; Singh, P; Kumari, R; Verma, H; Tripathi, C; ... & Lal, R. Microbial taxonomy in the era of OMICS: application of DNA sequences, computational tools and techniques. *Antonie Van Leeuwenhoek*, **2017**. 110, 1357-1371.
55. Otani, H; Uduary, D. W; & Mouncey, N. J. Comparative and pangenomic analysis of the genus *Streptomyces*. *Scientific rep*, **2022**. 12(1), 18909
56. Skinnider, M. A; Johnston, C. W; Gunabalasingam, M; Merwin, N. J; Kieliszek, A. M; MacLellan, R. J; ... & Magarvey, N. A. Comprehensive prediction of secondary metabolite structure and biological activity from microbial genome sequences. *Nature communications*, **2020**. 11(1), 6058
57. Ejigu, G. F; & Jung, J. Review on the computational genome annotation of sequences obtained by next-generation sequencing. *Biology*, **2020**. 9(9), 295.
58. Guan, N; Li, J; Shin, H. D; Du, G; Chen, J; & Liu, L. Microbial response to environmental stresses: from fundamental mechanisms to practical applications. *Appl Microbiol Biotechnol* **2017**. 101, 3991-4008.
59. Chandra, P; Enespa, Singh, R; & Arora, P. K. Microbial lipases and their industrial applications: a comprehensive review. *Microbial cell factories*, **2020**. 19, 1-42.
60. Barber, E. A; Liu, Z; & Smith, S. R. Organic contaminant biodegradation by oxidoreductase enzymes in wastewater treatment. *Microorganisms*, **2020**. 8(1), 122
61. Huang, X; Pinto, D; Fritz, G; & Mascher, T. Environmental sensing in Actinobacteria: a comprehensive survey on the signaling capacity of this phylum. *J Bacteriol*, **2015**. 197(15), 2517-2535.
62. Qin, S; Feng, W. W; Wang, T. T; Ding, P; Xing, K; & Jiang, J. H. Plant growth promoting effect and genomic analysis of the beneficial endophyte *Streptomyces* sp. KLBMP 5084 isolated from halophyte *Limonium sinense*. *Plant and Soil*, **2017**. 416, 117-132
63. Undabarrena, A; Ugalde, J. A; Seeger, M; & Cámara, B. Genomic data mining of the marine actinobacteria *Streptomyces* sp. H-KF8 unveils insights into multi-stress related genes and metabolic pathways involved in antimicrobial synthesis. *PeerJ*, **2017**. 5, e2912
64. Li, S; Li, Z; Pang, S; Xiang, W; & Wang, W. Coordinating precursor supply for pharmaceutical polyketide production in *Streptomyces*. *Curr Opin Biotechnol*, **2021**. 69, 26-34.
65. Cheng, M; Chen, D; Parales, R. E; & Jiang, J. Oxygenases as powerful weapons in the microbial degradation of pesticides. *Ann Rev Microbiol*, **2022**. 76(1), 325-348.
66. Palazzotto, E; & Weber, T. Omics and multi-omics approaches to study the biosynthesis of secondary metabolites in microorganisms. *Curr Opin Microbiol*, **2018**. 109-116.
67. van Bergeijk, D. A; Terlouw, B. R; Medema, M. H; & van Wezel, G. P. Ecology and genomics of Actinobacteria: new concepts for natural product discovery. *Nature Rev Microbiol*, **2020**. 18(10), 546-558.

68. Vicente, C. M; Thibessard, A; Lorenzi, J. N; Benhadj, M; Hôtel, L; Gacemi-Kirane, D; ... & Aigle, B. Comparative genomics among closely related *Streptomyces* strains revealed specialized metabolite biosynthetic gene cluster diversity. *Antibiotics*, **2018**. 7(4), 86.
69. Vijayakumar, R; Panneerselvam, K; Muthukumar, C; Thajuddin, N; Panneerselvam, A; & Saravanamuthu, R. Optimization of antimicrobial production by a marine actinomycete *Streptomyces afghaniensis* VPTS3-1 isolated from Palk Strait, East Coast of India. *Indian J Microbiol*, **2012**. 52, 230-239.
70. Sánchez, S; Chávez, A; Forero, A; García-Huante, Y; Romero, A; Sánchez, M; ... & Ruiz, B. Carbon source regulation of antibiotic production. *J Antibiotics*, **2010**. 63(8), 442-459.
71. Skarbek, J. D; & Brady, L. R. *Streptomyces cavourensis* sp. nov.(nom. rev.) and *Streptomyces cavourensis* subsp. *washingtonensis* subsp. nov; a chromomycin-producing subspecies. *Inter J Syst Evol Microbiol*, **1978**. 28, 45-53.
72. Xu, W; Zhang, D; Si, C; & Tao, L. Antifungal macrolides from *Streptomyces cavourensis* YY01-17. *Chemistry of Natural Compounds*, **2013**. 49, 988-989
73. Pan, H. Q; Yu, S. Y; Song, C. F; Wang, N; Hua, H. M; Hu, J. C; & Wang, S. J. Identification and characterization of the antifungal substances of a novel *Streptomyces cavourensis* NA4. *J Microbiol Biotechnol*, **2015**. 25(3)
74. Robertsen, H. L; & Musiol-Kroll, E. M. Actinomycete-derived polyketides as a source of antibiotics and lead structures for the development of new antimicrobial drugs. *Antibiotics*, **2019**. 8(4), 157
75. Álvarez-Álvarez, R; Botas, A; Albillos, S. M; Rumero, A; Martín, J. F; & Liras, P. Molecular genetics of naringenin biosynthesis, a typical plant secondary metabolite produced by *Streptomyces clavuligerus*. *Microbial Cell factories*, **2015**. 14, 1-12.
76. Martín, J. F; & Liras, P. Comparative molecular mechanisms of biosynthesis of naringenin and related chalcones in actinobacteria and plants: Relevance for the obtention of potent bioactive metabolites. *Antibiotics*, **2022**. 11(1), 82.
77. Salehi, B; Fokou, P. V. T; Sharifi-Rad, M; Zucca, P; Pezzani, R; Martins, N; & Sharifi- Rad, J. The therapeutic potential of naringenin: a review of clinical trials. *Pharmaceuticals*, **2019**. 12(1), 11.
78. Risdian, C; Mozef, T; & Wink, J. (2019). Biosynthesis of polyketides in *Streptomyces*. *Microorganisms*, 7(5), 124.
79. Rajesh, T; Tiwari, M. K; Thiagarajan, S; Nair, P. S; & Jeya, M. Type III polyketide synthases: current state and perspectives. *Microbial Technology for the Welfare of Society*, **2019**.183-200.
80. Santamaría, R. I; Martínez-Carrasco, A; Sánchez de la Nieta, R; Torres-Vila, L. M; Bonal, R; Martín, J; ... & Díaz, M. (2020). Characterization of actinomycetes strains isolated from the intestinal tract and feces of the larvae of the longhorn beetle *Cerambyx welensii*. *Microorganisms*, **2013**. 8(12),.
81. Krause, J. Applications and restrictions of integrated genomic and metabolomic screening: an accelerator for drug discovery from actinomycetes ?. *Molecules*, **2021**. 26(18), 5450.
82. Al-Quwaie, D. A. The role of *Streptomyces* species in controlling plant diseases: a comprehensive review. *Australasian Plant Pathology*, **2024**. 53(1), 1-14.
83. Hudson, G. A; & Mitchell, D. A. RiPP antibiotics: biosynthesis and engineering potential. *Curr Opin Microbiol*, **2018**. 45, 61-69

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.